Select a medication above to begin.
Unituxin
dinutuximab
Black Box Warnings .
Serious Infusion Reactions
serious, sometimes life-threatening infusion reactions occurred in 26% of patients; administer required prehydration and premed including antihistamines prior to each infusion; monitor patients closely for signs/symptoms during and for at least 4h following infusion; withhold tx for severe infusion reactions and permanently D/C for anaphylaxis
Neurotoxicity
including severe neuropathic pain and peripheral neuropathy; severe neuropathic pain occurred in the majority of patients; administer IV opioid prior to, during, and x2h following infusion; grade 3 peripheral sensory neuropathy occurred in 2-9% of patients; severe motor neuropathy has occurred; D/C for severe unresponsive pain, severe sensory neuropathy, or moderate-severe peripheral motor neuropathy
Adult Dosing .
Adult dosing is currently unavailable or not applicable for this drug.
Peds Dosing .
- Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, concomitant meds to mitigate toxicity, and dosing including toxicity-related dose adjustments
neuroblastoma, high-risk
- [17.5 mg/m^2/dose IV x1 for 4 days of each cycle]
- Info: give dose on days 4-7 of cycles 1, 3, 5 (24-day cycle); give dose on days 8-11 of cycles 2, 4 (32-day cycle); give up to 5 cycles; for patients with at least a partial response to prior tx; part of multi-drug chemo regimen; administer IV morphine immediately before, during, and x2h after end of infusion
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]